12/22/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Strattera

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Atomoxetin

Atomoxetin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Cohen JM, Srinivas C, Furu K, Cesta CE, Reutfors J, Karlstad Ø. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019. Eur J Clin Pharmacol. 2023;79(1):173-180.

  2. Nörby U, Winbladh B, Källén K. Perinatal Outcomes After Treatment With ADHD Medication During Pregnancy. Pediatrics. 2017 Nov 10. pii: e20170747.

  3. Diav-Citrin O, Shechtman S, Arnon J, Wajnberg R, Borisch C, Beck E et al. Methylphenidate in Pregnancy: A Multicenter, Prospective, Comparative, Observational Study. J Clin Psychiatry. 2016;77:1176-1181.

  4. Pottegård A, Hallas J, Andersen JT, Løkkegaard EC, Dideriksen D, Aagaard L et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75:e88-93.

  5. Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23:526-33.

  6. Bro SP, Kjaersgaard MI, Parner ET, Sørensen MJ, Olsen J, Bech BH et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139-47.

  7. Dideriksen D, Pottegård A, Hallas J, Aagaard L, Damkier P. First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol. 2013;112:73-6.

  8. Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K et al. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. JAMA Psychiatry. JAMA Psychiatry. 2017 Dec 13. doi: 10.1001/jamapsychiatry.2017.3644. [Epub ahead of print].

  9. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N et al. Associations Between ADHD Medication Use in Pregnancy and Severe Malformations Based on Prenatal and Postnatal Diagnoses: A Danish Registry-Based Study. J Clin Psychiatry. 2021;82(1):0.

  10. Cohen JM, Hernández-Díaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, Patorno E, Mogun H, Huybrechts KF. Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstet Gynecol. 2017 Nov 3. doi: 10.1097/AOG.0000000000002362.

  11. Bang Madsen K, Robakis TK, Liu X, Momen N, Larsson H, Dreier JW et al. In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry. 2023;0(0):0.

  12. Suarez EA, Bateman BT, Hernandez-Diaz S, Straub L, McDougle CJ, Wisner KL, Gray KJ, Pennell PB, Lester B, Zhu Y, Mogun H, Huybrechts KF. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. JAMA Psychiatry. 2024 Jan 24:e235073. doi: 10.1001/jamapsychiatry.2023.5073. Epub ahead of print. PMID: 38265792; PMCID: PMC10809143.

  13. Eriksson M, Jonsson B, Zetterström R. Children of mothers abusing amphetamine: head circumference during infancy and psychosocial development until 14 years of age. Acta Paediat 2000;89:1474-78.

  14. Eriksson M, Jonsson B, Steneroth G et al. Amphetamine abuse during pregnancy: environmental factors and outcome after 14-15 years. Scand J Public Health 2000;28:154-7.

  15. Besag FM. ADHD treatment and pregnancy. Drug Saf. 2014;37:397-408.

  16. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6:1221-86.

  17. Golub M, Costa L, Crofton K, Frank D, Fried P, Gladen B et al. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine. Birth Defects Res B Dev Reprod Toxicol. 2005;74:471-584.

  18. Ladhani NN, Shah PS, Murphy KE, Knowledge Synthesis Group on Determinants of Preterm/LBW Births. Prenatal amphetamine exposure and birth outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011;205:219e1-7.

  19. Chomchai C, Na Manorom N, Watanarungsan P, Yossuck P, Chomchai S. Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand. Southeast Asian J Trop Med Public Health. 2004;35:228-31.

  20. Thaithumyanon P, Limpongsanurak S, Praisuwanna P, Punnahitanon S. Perinatal effects of amphetamine and heroin use during pregnancy on the mother and infant. J Med Assoc Thai. 2005;88:1506-13.

  21. Bröms G, Hernandez-Diaz S, Huybrechts KF, Bateman BT, Kristiansen EB, Einarsdóttir K et al. Atomoxetine in Early Pregnancy and the Prevalence of Major Congenital Malformations: A Multinational Study. J Clin Psychiatry. 2023;84(1).

  1. Cohen JM, Srinivas C, Furu K, Cesta CE, Reutfors J, Karlstad Ø. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019. Eur J Clin Pharmacol. 2023;79(1):173-180.
  2. Nörby U, Winbladh B, Källén K. Perinatal Outcomes After Treatment With ADHD Medication During Pregnancy. Pediatrics. 2017 Nov 10. pii: e20170747.
  3. Diav-Citrin O, Shechtman S, Arnon J, Wajnberg R, Borisch C, Beck E et al. Methylphenidate in Pregnancy: A Multicenter, Prospective, Comparative, Observational Study. J Clin Psychiatry. 2016;77:1176-1181.
  4. Pottegård A, Hallas J, Andersen JT, Løkkegaard EC, Dideriksen D, Aagaard L et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75:e88-93.
  5. Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23:526-33.
  6. Bro SP, Kjaersgaard MI, Parner ET, Sørensen MJ, Olsen J, Bech BH et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139-47.
  7. Dideriksen D, Pottegård A, Hallas J, Aagaard L, Damkier P. First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol. 2013;112:73-6.
  8. Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K et al. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. JAMA Psychiatry. JAMA Psychiatry. 2017 Dec 13. doi: 10.1001/jamapsychiatry.2017.3644. [Epub ahead of print].
  9. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N et al. Associations Between ADHD Medication Use in Pregnancy and Severe Malformations Based on Prenatal and Postnatal Diagnoses: A Danish Registry-Based Study. J Clin Psychiatry. 2021;82(1):0.
  10. Cohen JM, Hernández-Díaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, Patorno E, Mogun H, Huybrechts KF. Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstet Gynecol. 2017 Nov 3. doi: 10.1097/AOG.0000000000002362.
  11. Bang Madsen K, Robakis TK, Liu X, Momen N, Larsson H, Dreier JW et al. In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry. 2023;0(0):0.
  12. Suarez EA, Bateman BT, Hernandez-Diaz S, Straub L, McDougle CJ, Wisner KL, Gray KJ, Pennell PB, Lester B, Zhu Y, Mogun H, Huybrechts KF. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. JAMA Psychiatry. 2024 Jan 24:e235073. doi: 10.1001/jamapsychiatry.2023.5073. Epub ahead of print. PMID: 38265792; PMCID: PMC10809143.
  13. Eriksson M, Jonsson B, Zetterström R. Children of mothers abusing amphetamine: head circumference during infancy and psychosocial development until 14 years of age. Acta Paediat 2000;89:1474-78.
  14. Eriksson M, Jonsson B, Steneroth G et al. Amphetamine abuse during pregnancy: environmental factors and outcome after 14-15 years. Scand J Public Health 2000;28:154-7.
  15. Besag FM. ADHD treatment and pregnancy. Drug Saf. 2014;37:397-408.
  16. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6:1221-86.
  17. Golub M, Costa L, Crofton K, Frank D, Fried P, Gladen B et al. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine. Birth Defects Res B Dev Reprod Toxicol. 2005;74:471-584.
  18. Ladhani NN, Shah PS, Murphy KE, Knowledge Synthesis Group on Determinants of Preterm/LBW Births. Prenatal amphetamine exposure and birth outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011;205:219e1-7.
  19. Chomchai C, Na Manorom N, Watanarungsan P, Yossuck P, Chomchai S. Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand. Southeast Asian J Trop Med Public Health. 2004;35:228-31.
  20. Thaithumyanon P, Limpongsanurak S, Praisuwanna P, Punnahitanon S. Perinatal effects of amphetamine and heroin use during pregnancy on the mother and infant. J Med Assoc Thai. 2005;88:1506-13.
  21. Bröms G, Hernandez-Diaz S, Huybrechts KF, Bateman BT, Kristiansen EB, Einarsdóttir K et al. Atomoxetine in Early Pregnancy and the Prevalence of Major Congenital Malformations: A Multinational Study. J Clin Psychiatry. 2023;84(1).